Aaron Rosenberg - BeiGene Chief Officer

49BA Stock  EUR 296.00  6.00  2.07%   

Executive

Aaron Rosenberg is Chief Officer of BeiGene
Age 49
Phone41 61 685 19 00
Webhttps://beonemedicines.com

Aaron Rosenberg Latest Insider Activity

Tracking and analyzing the buying and selling activities of Aaron Rosenberg against BeiGene stock is an integral part of due diligence when investing in BeiGene. Aaron Rosenberg insider activity provides valuable insight into whether BeiGene is net buyers or sellers over its current business cycle. Note, BeiGene insiders must abide by specific rules, including filing SEC forms every time they buy or sell BeiGene'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

BeiGene Management Efficiency

The company has return on total asset (ROA) of 0.0169 % which means that it generated a profit of $0.0169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0181 %, meaning that it generated $0.0181 on every $100 dollars invested by stockholders. BeiGene's management efficiency ratios could be used to measure how well BeiGene manages its routine affairs as well as how well it operates its assets and liabilities.
BeiGene has accumulated 851.53 M in total debt with debt to equity ratio (D/E) of 17.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BeiGene has a current ratio of 6.33, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BeiGene until it has trouble settling it off, either with new capital or with free cash flow. So, BeiGene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BeiGene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BeiGene to invest in growth at high rates of return. When we think about BeiGene's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 7 records

EXECUTIVE Age

Pui CPASunny Optical Technology
44
Tan WangSunny Optical Technology
50
Marko WernerSMA Solar Technology
63
Kaveh RouhiSMA Solar Technology
N/A
William CawkerNicola Mining
N/A
Will WhittyNicola Mining
N/A
Julia DammSMA Solar Technology
N/A
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the Peoples Republic of China, the United States, and internationally. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the Peoples Republic of China. BEIGENE LTD is traded on Frankfurt Stock Exchange in Germany. BeiGene (49BA) is traded on Frankfurt Exchange in Germany and employs 11,000 people. BeiGene is listed under Biotechnology category by Fama And French industry classification.

Management Performance

BeiGene Leadership Team

Elected by the shareholders, the BeiGene's board of directors comprises two types of representatives: BeiGene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BeiGene. The board's role is to monitor BeiGene's management team and ensure that shareholders' interests are well served. BeiGene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BeiGene's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Oyler, Executive CoFounder
Xiaodong Wang, Chairman CoFounder
Mi Zhou, Director Relations
Marcello Damiani, Chief Officer
Liza Heapes, Head Relations
Chan Lee, General VP
Wang Lai, President Development
Eleanor Duff, Senior Communications
Kevin Mannix, VP Relations
Titus Ball, VP Officer
Julia Wang, CFO Officer
Aaron Rosenberg, Chief Officer
Daniel Maller, VP Accounting
Diana Francis, VP Compliance
Xiaobin Wu, COO Pres
Mark Lanasa, Senior Tumors

BeiGene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BeiGene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether BeiGene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BeiGene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Beigene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Beigene Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more detail on how to invest in BeiGene Stock please use our How to Invest in BeiGene guide.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Understanding that BeiGene's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether BeiGene represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.